Squeeze a Panic Pete stress toy and the reaction is immediate: eyes, ears, and nose all bulge outward. It’s also predictable: same input, same output, every time. But most systems — especially markets — do not behave that way. Squeeze one part and it is genuinely hard to know which parts will bulge, which will contract, and which will not move at all.
The rise of direct-to-consumer (DTC) sales channels for GLP-1 obesity medicines is that kind of squeeze. Eli Lilly now offers obesity medicines through LillyDirect, including self-pay pathways and home delivery. Novo Nordisk has built similar options for Wegovy through NovoCare Pharmacy. These channels promise convenience, transparent pricing, and a path to treatment that bypasses the traditional payer relationship — a particularly relevant distinction because GLP-1 coverage for diabetes is largely settled, while coverage for weight loss remains contested. The central question is what this means for coverage decisions. The answer is not straightforward, because DTC sales create forces that pull in opposite directions.
Forces that could reduce coverage pressure
The most direct path runs through demand relief. If patients who can afford to self-pay do so, they exit the pool of people pushing insurers and employers for coverage. Plans may face fewer appeals and less political pressure to add a costly benefit. The strength of this effect depends on how many patients can actually sustain out-of-pocket costs — and at $350 per month for injectables, that is a limited population. Some employers are already acting on this logic, offering employees $100 or $200 per month toward DTC sales purchases rather than assuming the full actuarial risk of a covered benefit.
DTC sales channels may widen a two-class divide: Wealthier patients self-pay while others rely on insurance. The DTC channel offers real advantages: access to doses above what plans typically authorize, no prior-authorization delays, and no coverage restrictions like BMI thresholds, comorbidities, or other clinical criteria. If wealthier patients self-pay at scale, the remaining insured population may skew toward lower-income, higher-risk members. That would not eliminate coverage pressure, but it would narrow it to a clinically defined group — making targeted coverage easier for payers to defend than broad, open-ended obesity coverage. Whether enough patients find these advantages compelling to stay in the cash-pay channel is an open question.
DTC sales will also generate real-world evidence on persistence and tolerability. If that evidence shows that many patients stop treatment early, it may strengthen the case against broad coverage. Studies have found that more than half of patients without type 2 diabetes discontinued GLP-1s within one year. Clinical trials have documented substantial weight regain following discontinuation. That weakens the return on investment payers would expect from broad coverage. Payers confronted with real-world discontinuation data may find it easier to justify tighter criteria or required evidence of early response — though some discontinuation in insured populations reflects payer-imposed barriers like high cost sharing and reauthorization requirements rather than patients’ unwillingness to remain on therapy.
Broader use through these channels may also produce safety signals less visible in trials. Studies have found that reductions in lean muscle mass account for roughly 25 percent of weight lost on GLP-1s. Clinicians generally view these changes as adaptive in most patients, but older adults and those with muscle-wasting conditions face higher risk. If real-world use surfaces higher rates of muscle loss or functional decline in specific subpopulations, payers may respond by narrowing eligibility or adding monitoring requirements. Broad coverage is harder to justify for a therapy that requires more patient selection and oversight.
Coverage contraction is already underway. Blue Cross Blue Shield of Massachusetts announced in April 2025 that it would drop standard GLP-1 weight-loss coverage, effective January 2026, and several other BCBS affiliates followed. Among employers with 5,000 or more workers, the share covering GLP-1s for weight loss rose from 28 percent in 2024 to 43 percent in 2025, but many have reported higher-than-expected utilization and cost pressure, and some now restrict coverage to employees with indications like diabetes. Several Medicaid programs dropped or restricted GLP-1 coverage in 2025 and 2026.
Forces that could increase coverage pressure
More treated patients create peer effects, surface latent demand, and change what patients, employers, and clinicians regard as standard of care. Once a therapy is widely initiated outside the benefit, the payer debate shifts from whether obesity should be treated at all to which patients should be covered and under what limits. That shift raises the political and reputational cost of holding the line on restrictive coverage.
Once a therapy becomes easier to initiate outside the benefit, the noncoverage burden shifts. Plans face more pressure to explain why a drug available that afternoon at cash-pay prices is not covered. Members who start on cash-pay pricing and later find it unsustainable may return to their health plan seeking covered access — at which point, applying prior authorization or step therapy becomes difficult without appearing to interrupt an established course of treatment.
Cash-pay prices create reference points commercial payers cannot ignore. PBMs are expected to push for comparable net costs — and if commercial members continue to face costs well above what they could pay directly, that gap will be difficult for employers and plans to defend.
Another effect runs through how payers read the demand they do see. If insurance were the only path to treatment, some patients who wouldn’t qualify would have had an incentive to game the system — overstating a BMI, leaning on a borderline comorbidity — because coverage would otherwise have been out of reach. DTC sales reduce that incentive by offering an alternative path. The utilization that remains in the covered channel is then more likely to reflect genuine clinical need — and a cleaner, more legitimate demand signal makes coverage easier for payers to defend and easier to expand.
The budget case may also improve. If a meaningful share of wealthier patients self-pay rather than seeking covered access, payers’ covered population would shrink, lowering budget exposure.
Real-world evidence can also strengthen the economic case for coverage. If the utilization generated through DTC sales channels can be linked to downstream reductions in cardiovascular events, hospitalizations, or other costly complications, manufacturers and advocates gain a stronger argument that coverage is not just clinically justified but economically defensible. Lilly and Novo Nordisk are expanding the treated population from whom market-relevant evidence can accumulate. That evidence could make it difficult for payers to justify restrictive coverage policies.
Cash-pay channels may also yield cleaner evidence of persistence. Cash-pay patients face none of the reauthorization hurdles, cost-sharing requirements, or step therapy barriers that drive discontinuation in insured populations. If persistence among cash-pay patients proves stronger than among insured patients, it would suggest that poor persistence is not simply a property of the drugs themselves — making it harder for payers to defend restrictive coverage on the ground that real-world use is inherently unsustainable.
DTC sales expand the number of patients using these drugs, which accelerates the accumulation of real-world evidence across all indications — not just weight loss. GLP-1s already carry approvals for cardiovascular risk reduction, kidney disease, and liver disease in people with type 2 diabetes, and trials in osteoarthritis and addiction are underway. Each new indication makes the drug class look less like a weight-loss intervention and more like a treatment platform for serious metabolic disease. That makes it harder for payers to dismiss obesity coverage as paying for a lifestyle choice.
The political landscape also remains alive, even if legislative momentum has slowed. North Dakota updated its ACA essential health benefit benchmark effective January 2025 to require GLP-1 coverage for specific clinical indications in individual and small-group plans — the only state insurance coverage requirement to date. The North Dakota precedent does not establish a trend, but it shows that coverage mandates have not disappeared from state-policy debates.
The squeeze
The coverage question is not going away. The forces DTC sales set in motion pull in too many directions, and the evidence needed to settle them is still arriving. Unlike a Panic Pete toy, the final shape of the coverage response is hard to predict — but given how many Americans are living with obesity or struggling with their weight and the cost of the drugs, the outcome could be eye-popping.
No Comments